Maple Grove, Minnesota, December 1, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472) today announced that Upsher-Smith Laboratories, LLC (“Upsher-Smith”), its pharma sales subsidiary, launched KYMBEE™ (deflazacort) Tablets in the United States, a branded generic indicated for the treatment of Duchenne Muscular Dystrophy (DMD) in patients 5 years of age and older. In addition, Upsher-Smith’s flagship specialty product VIGAFYDE® (vigabatrin) Oral Solution, was featured in November at the Epilepsy Awareness & Education Expo at Disneyland Resort in California, one of the world’s largest gatherings of epilepsy specialists, patients, and caregivers. The Company continues to advance patient support services while building a stronger presence in the pediatric neurology vertical.
Bobby Sheng, Chairman and CEO of Bora Group, stated: “Following the approval of Deflazacort Tablets back in January, we were able to now introduce the branded generic through the availability of KYMBEE™ and our Promise of Support® Program. We’re proud to offer a U.S.-manufactured product, backed by our comprehensive support program designed to help ease some of the challenges associated with prescribing and accessing deflazacort.”
In addition to the latest success of KYMBEE™, VIGAFYDE® continues to display strong market potential. In fact, Upsher-Smith was invited to the Epilepsy Awareness & Education Expo at Disneyland Resort in California in November for National Epilepsy Awareness Month. Viggy, the friendly purple dragon mascot of VIGAFYDE®, along with specialty pharma sales team, engaged with patients, families, healthcare professionals and advocates through educational materials and kid-friendly activities to raise public awareness and support for epilepsy and rare disease care.
US based healthcare intelligence company Towards Healthcare estimates that the north American non-NCE branded pharmaceuticals market will grow at a CAGR of 8.47%, reaching US$867.2 billion by 2035. By combining the cost advantages of generics with greater brand recognition and trust through services, branded generics enhance patient confidence in product quality and encourage prescribing by healthcare professionals and are therefore playing an increasingly important role in healthcare systems worldwide.